A chemical biology screen identifies a vulnerability of neuroendocrine cancer cells to SQLE inhibition

Journal: Nature Communications

Published: 2019-01-09

DOI: 10.1038/s41467-018-07959-4

Affiliations: 4

Authors: 29

Go to article
Institutions FC
Agios Pharmaceuticals, Inc., United States of America (USA) 0.83
Shanghai ChemPartner Co., Ltd., China 0.14
Decibel Therapeutics, United States of America (USA) 0.02
Celsius Therapeutics, United States of America (USA) 0.02

Return